133 related articles for article (PubMed ID: 26964858)
61. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.
Judge AD; Bola G; Lee AC; MacLachlan I
Mol Ther; 2006 Mar; 13(3):494-505. PubMed ID: 16343994
[TBL] [Abstract][Full Text] [Related]
62. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
63. Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes.
Sebestyén MG; Wong SC; Trubetskoy V; Lewis DL; Wooddell CI
Methods Mol Biol; 2015; 1218():163-86. PubMed ID: 25319651
[TBL] [Abstract][Full Text] [Related]
64. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.
Broering R; Real CI; John MJ; Jahn-Hofmann K; Ickenstein LM; Kleinehr K; Paul A; Gibbert K; Dittmer U; Gerken G; Schlaak JF
Int Immunol; 2014 Jan; 26(1):35-46. PubMed ID: 24065781
[TBL] [Abstract][Full Text] [Related]
65. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
66. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
[TBL] [Abstract][Full Text] [Related]
67. Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol.
Nishina K; Unno T; Uno Y; Kubodera T; Kanouchi T; Mizusawa H; Yokota T
Mol Ther; 2008 Apr; 16(4):734-740. PubMed ID: 28178465
[TBL] [Abstract][Full Text] [Related]
68. A self-assembled DNA tetrahedron as a carrier for in vivo liver-specific delivery of siRNA.
Kim KR; Jegal H; Kim J; Ahn DR
Biomater Sci; 2020 Jan; 8(2):586-590. PubMed ID: 31913375
[TBL] [Abstract][Full Text] [Related]
69. Nanotubes functionalized with lipids and natural amino acid dendrimers: a new strategy to create nanomaterials for delivering systemic RNAi.
McCarroll J; Baigude H; Yang CS; Rana TM
Bioconjug Chem; 2010 Jan; 21(1):56-63. PubMed ID: 19957956
[TBL] [Abstract][Full Text] [Related]
70. Nanoparticle delivery systems for siRNA-based therapeutics.
Li J; Xue S; Mao ZW
J Mater Chem B; 2016 Nov; 4(41):6620-6639. PubMed ID: 32263517
[TBL] [Abstract][Full Text] [Related]
71. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis.
Desmet E; Bracke S; Forier K; Taevernier L; Stuart MC; De Spiegeleer B; Raemdonck K; Van Gele M; Lambert J
Int J Pharm; 2016 Mar; 500(1-2):268-74. PubMed ID: 26806466
[TBL] [Abstract][Full Text] [Related]
72. A simplified method for manufacturing RNAi therapeutics for local administration.
Ando H; Abu Lila AS; Fukushima M; Matsuoka R; Shimizu T; Okuhira K; Ishima Y; Huang CL; Wada H; Ishida T
Int J Pharm; 2019 Jun; 564():256-262. PubMed ID: 31015002
[TBL] [Abstract][Full Text] [Related]
73. An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA.
Adami RC; Seth S; Harvie P; Johns R; Fam R; Fosnaugh K; Zhu T; Farber K; McCutcheon M; Goodman TT; Liu Y; Chen Y; Kwang E; Templin MV; Severson G; Brown T; Vaish N; Chen F; Charmley P; Polisky B; Houston ME
Mol Ther; 2011 Jun; 19(6):1141-51. PubMed ID: 21505423
[TBL] [Abstract][Full Text] [Related]
74. Quick nuclear transportation of siRNA and in vivo hepatic ApoB gene silencing with galactose-bearing polymeric carrier.
Tachibana Y; Munisso MC; Kamata W; Kitagawa M; Harada-Shiba M; Yamaoka T
J Biotechnol; 2014 Apr; 175():15-21. PubMed ID: 24530538
[TBL] [Abstract][Full Text] [Related]
75. Lipid nanoparticle delivery systems for siRNA-based therapeutics.
Wan C; Allen TM; Cullis PR
Drug Deliv Transl Res; 2014 Feb; 4(1):74-83. PubMed ID: 25786618
[TBL] [Abstract][Full Text] [Related]
76. Hepatocyte-Directed Delivery of Lipid-Encapsulated Small Interfering RNA.
Morán L; Woitok MM; Bartneck M; Cubero FJ
Methods Mol Biol; 2022; 2544():95-106. PubMed ID: 36125712
[TBL] [Abstract][Full Text] [Related]
77. Development of novel lipidic particles for siRNA delivery that are highly effective after 12 months storage.
Clarke D; Idris A; McMillan NAJ
PLoS One; 2019; 14(2):e0211954. PubMed ID: 30735545
[TBL] [Abstract][Full Text] [Related]
78. Bioresponsive Chimaeric Polymersomes Mediate Sustained and Liver-Specific
Huang R; Wang F; Fu H; Qi X; Xing G; Ren J; Cheng L; Meng F; Zhong Z
Biomacromolecules; 2023 Nov; 24(11):5353-5363. PubMed ID: 37871289
[TBL] [Abstract][Full Text] [Related]
79. Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA.
McCaskill J; Singhania R; Burgess M; Allavena R; Wu S; Blumenthal A; McMillan NA
Mol Ther Nucleic Acids; 2013 Jun; 2(6):e96. PubMed ID: 23736774
[TBL] [Abstract][Full Text] [Related]
80. Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.
Novobrantseva TI; Borodovsky A; Wong J; Klebanov B; Zafari M; Yucius K; Querbes W; Ge P; Ruda VM; Milstein S; Speciner L; Duncan R; Barros S; Basha G; Cullis P; Akinc A; Donahoe JS; Narayanannair Jayaprakash K; Jayaraman M; Bogorad RL; Love K; Whitehead K; Levins C; Manoharan M; Swirski FK; Weissleder R; Langer R; Anderson DG; de Fougerolles A; Nahrendorf M; Koteliansky V
Mol Ther Nucleic Acids; 2012 Jan; 1(1):e4. PubMed ID: 23344621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
